A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD)
2022-06-29
عنوان الدراسة
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care(FIGARO -DKD)
داعم الدراسة
Bayer
دواء الدراسة
Finerenone
رقم بروتوكول الدراسة
BAY 94-8862 17530
حالة الدراسة
Terminated
موقع الدراسة
KAUH-J
مرحلة الدراسة
3
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.